Streetbeat News

Analyst Ratings

TH

Stifel analyst Stephen Gengaro has maintained a Buy rating on Target Hospitality (NASDAQ:TH) and kept the price target at $13.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:24 pm

STX

WDC

Western Digital's stock is trading higher, potentially due to Seagate's stock rise following an upgrade from Morgan Stanley. This suggests a sympathetic movement in the sector influenced by analyst ratings.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:22 pm

IR

Stifel analyst Nathan Jones has maintained a Buy rating on Ingersoll Rand (NYSE:IR) and has also maintained a price target of $102 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:21 pm

SYRE

Stifel analyst Alex Thompson has reiterated a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $36 to $54, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:18 pm

CLH

Stifel analyst Michael Hoffman has reiterated a Buy rating on Clean Harbors (NYSE:CLH) and increased the price target from $206 to $210.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:17 pm

ZM

Rosenblatt analyst Catharine Trebnick has reiterated a Neutral rating on Zoom Video Communications (ZM) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:15 pm

TNDM

Stifel analyst Mathew Blackman upgraded Tandem Diabetes Care (TNDM) from Hold to Buy and increased the price target from $24 to $37.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:15 pm

BKKT

Rosenblatt analyst Andrew Bond has reiterated a Buy rating on Bakkt Holdings (NYSE:BKKT) and maintained a price target of $0.75.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:13 pm

HSY

Exane BNP Paribas analyst Max Gumport downgraded Hershey (HSY) from Outperform to Neutral and set a price target of $208.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:08 pm

DYN

Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Dyne Therapeutics (NASDAQ:DYN) and maintains a $47 price target.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:07 pm